🎉 M&A multiples are live!
Check it out!

Gland Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Gland Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Gland Pharma Overview

About Gland Pharma

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.


Founded

1978

HQ

India
Employees

4.2K+

Website

glandpharma.com

Financials

LTM Revenue $675M

LTM EBITDA $154M

EV

$2.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Gland Pharma Financials

Gland Pharma has a last 12-month revenue of $675M and a last 12-month EBITDA of $154M.

In the most recent fiscal year, Gland Pharma achieved revenue of $655M and an EBITDA of $174M.

Gland Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Gland Pharma valuation multiples based on analyst estimates

Gland Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $417M $655M XXX XXX XXX
Gross Profit $264M $221M XXX XXX XXX
Gross Margin 63% 34% XXX XXX XXX
EBITDA $140M $174M XXX XXX XXX
EBITDA Margin 34% 27% XXX XXX XXX
Net Profit $141M $90.7M XXX XXX XXX
Net Margin 34% 14% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Gland Pharma Stock Performance

As of April 15, 2025, Gland Pharma's stock price is INR 1394 (or $16).

Gland Pharma has current market cap of INR 230B (or $2.7B), and EV of INR 204B (or $2.4B).

See Gland Pharma trading valuation data

Gland Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.4B $2.7B XXX XXX XXX XXX $0.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Gland Pharma Valuation Multiples

As of April 15, 2025, Gland Pharma has market cap of $2.7B and EV of $2.4B.

Gland Pharma's trades at 3.5x LTM EV/Revenue multiple, and 15.4x LTM EBITDA.

Analysts estimate Gland Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Gland Pharma and 10K+ public comps

Gland Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.4B XXX XXX XXX
EV/Revenue 3.5x XXX XXX XXX
EV/EBITDA 15.0x XXX XXX XXX
P/E 31.3x XXX XXX XXX
P/E/Growth 1.3x XXX XXX XXX
EV/FCF 48.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gland Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Gland Pharma Valuation Multiples

Gland Pharma's NTM/LTM revenue growth is 12%

Gland Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Gland Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Gland Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Gland Pharma and other 10K+ public comps

Gland Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 57% XXX XXX XXX XXX
EBITDA Margin 24% XXX XXX XXX XXX
EBITDA Growth 24% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 35% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 1% XXX XXX XXX XXX
Opex to Revenue 44% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Gland Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Gland Pharma M&A and Investment Activity

Gland Pharma acquired  XXX companies to date.

Last acquisition by Gland Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Gland Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Gland Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Gland Pharma

When was Gland Pharma founded? Gland Pharma was founded in 1978.
Where is Gland Pharma headquartered? Gland Pharma is headquartered in India.
How many employees does Gland Pharma have? As of today, Gland Pharma has 4.2K+ employees.
Who is the CEO of Gland Pharma? Gland Pharma's CEO is Mr. Shyamakant Giri.
Is Gland Pharma publicy listed? Yes, Gland Pharma is a public company listed on NSE.
What is the stock symbol of Gland Pharma? Gland Pharma trades under GLAND ticker.
When did Gland Pharma go public? Gland Pharma went public in 2020.
Who are competitors of Gland Pharma? Similar companies to Gland Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Gland Pharma? Gland Pharma's current market cap is $2.7B
What is the current revenue of Gland Pharma? Gland Pharma's last 12-month revenue is $675M.
What is the current EBITDA of Gland Pharma? Gland Pharma's last 12-month EBITDA is $154M.
What is the current EV/Revenue multiple of Gland Pharma? Current revenue multiple of Gland Pharma is 3.5x.
What is the current EV/EBITDA multiple of Gland Pharma? Current EBITDA multiple of Gland Pharma is 15.4x.
What is the current revenue growth of Gland Pharma? Gland Pharma revenue growth between 2023 and 2024 was 57%.
Is Gland Pharma profitable? Yes, Gland Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.